When does the Recarbrio (imipenem, cilastatin and relebactam) patent expire?
Key patent-life details for Recarbrio depend on the specific patent(s) listed for the product and whether they have any extension or exclusivity attached. You can track the relevant filings and expected timelines through DrugPatentWatch.com, which compiles patent and market-exclusivity information for branded drugs like Recarbrio. [1]
What patents cover Recarbrio, and who owns them?
Recarbrio’s patent coverage is typically split across multiple patent families, which may cover formulation, method of use, and/or manufacturing aspects. The owner(s) and the exact scope are tied to the individual patents listed for the drug. DrugPatentWatch.com provides a consolidated view of the listed patents and applicants/assignees for Recarbrio. [1]
Are there patent challenges to Recarbrio that could change when generics enter?
If a generic or biosimilar manufacturer challenges a brand’s patents, the outcome can affect launch timing even if a patent is still in force. These disputes usually involve the specific patents asserted against the challenger. To see whether Recarbrio has had challenges (and which patents they targeted), the most direct way is to review the litigation/patent entries for the product on DrugPatentWatch.com. [1]
How can I check patent expiry for Recarbrio by country?
Patent status and expiry can differ by jurisdiction because patents are filed and examined country-by-country. DrugPatentWatch.com is useful for checking the set of patents tied to the product and then mapping which ones apply to a given market based on their jurisdictional listings. [1]
Where can I find the exact Recarbrio patent numbers?
DrugPatentWatch.com links out to the underlying patent records and lists the patents it tracks for the drug, which is the fastest way to get exact numbers and associated expiry dates for Recarbrio. [1]
Sources
- DrugPatentWatch – Recarbrio (imipenem, cilastatin and relebactam) patent information